These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 32089220)

  • 1. Targeting TP53 Mutations in Myelodysplastic Syndromes.
    Hunter AM; Sallman DA
    Hematol Oncol Clin North Am; 2020 Apr; 34(2):421-440. PubMed ID: 32089220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic impact of variant allele frequency (VAF) in TP53 mutant patients with MDS: A systematic review and meta-analysis.
    Deng J; Wu X; Ling Y; Liu X; Zheng X; Ye W; Gong Y
    Eur J Haematol; 2020 Nov; 105(5):524-539. PubMed ID: 32621334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype.
    Wang W; Routbort MJ; Tang Z; Ok CY; Patel KP; Daver N; Garcia-Manero G; Medeiros LJ; Wang SA
    Eur J Haematol; 2017 Dec; 99(6):536-543. PubMed ID: 28926144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role Of TP53 mutations in predicting the clinical efficacy of hypomethylating therapy in patients with myelodysplastic syndrome and related neoplasms: a systematic review and meta-analysis.
    Cai L; Zhao X; Ai L; Wang H
    Clin Exp Med; 2020 Aug; 20(3):361-371. PubMed ID: 32613269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
    Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications.
    Zhang L; McGraw KL; Sallman DA; List AF
    Leuk Lymphoma; 2017 Aug; 58(8):1777-1790. PubMed ID: 27967292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eprenetapopt (APR-246) and Azacitidine in
    Sallman DA; DeZern AE; Garcia-Manero G; Steensma DP; Roboz GJ; Sekeres MA; Cluzeau T; Sweet KL; McLemore A; McGraw KL; Puskas J; Zhang L; Yao J; Mo Q; Nardelli L; Al Ali NH; Padron E; Korbel G; Attar EC; Kantarjian HM; Lancet JE; Fenaux P; List AF; Komrokji RS
    J Clin Oncol; 2021 May; 39(14):1584-1594. PubMed ID: 33449813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.
    Takahashi K; Patel K; Bueso-Ramos C; Zhang J; Gumbs C; Jabbour E; Kadia T; Andreff M; Konopleva M; DiNardo C; Daver N; Cortes J; Estrov Z; Futreal A; Kantarjian H; Garcia-Manero G
    Oncotarget; 2016 Mar; 7(12):14172-87. PubMed ID: 26871476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations of myelodysplastic syndromes (MDS): An update.
    Ganguly BB; Kadam NN
    Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Epigenomic Hypermethylation at TP53 on Allogeneic Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndromes.
    Wang W; Auer P; Zhang T; Spellman S; Carlson KS; Nazha A; Bolon YT; Saber W
    Transplant Cell Ther; 2021 Aug; 27(8):659.e1-659.e6. PubMed ID: 33992829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation-Driven Therapy in MDS.
    Swoboda DM; Sallman DA
    Curr Hematol Malig Rep; 2019 Dec; 14(6):550-560. PubMed ID: 31760573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.
    Bernard E; Nannya Y; Hasserjian RP; Devlin SM; Tuechler H; Medina-Martinez JS; Yoshizato T; Shiozawa Y; Saiki R; Malcovati L; Levine MF; Arango JE; Zhou Y; Solé F; Cargo CA; Haase D; Creignou M; Germing U; Zhang Y; Gundem G; Sarian A; van de Loosdrecht AA; Jädersten M; Tobiasson M; Kosmider O; Follo MY; Thol F; Pinheiro RF; Santini V; Kotsianidis I; Boultwood J; Santos FPS; Schanz J; Kasahara S; Ishikawa T; Tsurumi H; Takaori-Kondo A; Kiguchi T; Polprasert C; Bennett JM; Klimek VM; Savona MR; Belickova M; Ganster C; Palomo L; Sanz G; Ades L; Della Porta MG; Elias HK; Smith AG; Werner Y; Patel M; Viale A; Vanness K; Neuberg DS; Stevenson KE; Menghrajani K; Bolton KL; Fenaux P; Pellagatti A; Platzbecker U; Heuser M; Valent P; Chiba S; Miyazaki Y; Finelli C; Voso MT; Shih LY; Fontenay M; Jansen JH; Cervera J; Atsuta Y; Gattermann N; Ebert BL; Bejar R; Greenberg PL; Cazzola M; Hellström-Lindberg E; Ogawa S; Papaemmanuil E
    Nat Med; 2020 Oct; 26(10):1549-1556. PubMed ID: 32747829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.
    Haase D; Stevenson KE; Neuberg D; Maciejewski JP; Nazha A; Sekeres MA; Ebert BL; Garcia-Manero G; Haferlach C; Haferlach T; Kern W; Ogawa S; Nagata Y; Yoshida K; Graubert TA; Walter MJ; List AF; Komrokji RS; Padron E; Sallman D; Papaemmanuil E; Campbell PJ; Savona MR; Seegmiller A; Adès L; Fenaux P; Shih LY; Bowen D; Groves MJ; Tauro S; Fontenay M; Kosmider O; Bar-Natan M; Steensma D; Stone R; Heuser M; Thol F; Cazzola M; Malcovati L; Karsan A; Ganster C; Hellström-Lindberg E; Boultwood J; Pellagatti A; Santini V; Quek L; Vyas P; Tüchler H; Greenberg PL; Bejar R;
    Leukemia; 2019 Jul; 33(7):1747-1758. PubMed ID: 30635634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
    Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
    J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Ball S; Loghavi S; Zeidan AM
    Leuk Lymphoma; 2023 Mar; 64(3):540-550. PubMed ID: 36323304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TP53 mutations are associated with very complex karyotype and suggest poor prognosis in newly diagnosed myelodysplastic syndrome patients with monosomal karyotype.
    Ren Y; Wang J; Zhang H; Mei C; Ye L; Luo Y; Zhou X; Zhu S; Jiang L; Wang L; Jin J; Tong H
    Asia Pac J Clin Oncol; 2020 Jun; 16(3):172-179. PubMed ID: 32030889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Life after hypomethylating agents in myelodysplastic syndrome: new strategies.
    Santini V
    Curr Opin Hematol; 2015 Mar; 22(2):155-62. PubMed ID: 25603477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis.
    Loghavi S; Al-Ibraheemi A; Zuo Z; Garcia-Manero G; Yabe M; Wang SA; Kantarjian HM; Yin CC; Miranda RN; Luthra R; Medeiros LJ; Bueso-Ramos CE; Khoury JD
    Br J Haematol; 2015 Oct; 171(1):91-9. PubMed ID: 26123119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia.
    Cluzeau T; Loschi M; Fenaux P; Komrokji R; Sallman DA
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
    Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
    Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.